Advertisement

Clinical and Translational Oncology

, Volume 18, Issue 8, pp 859–862 | Cite as

Late recurrence (more than 10 years) in early (tumors equal to or smaller than 2 cm) breast cancer patients

  • J. GiulianiEmail author
  • A. Mercanti
  • A. Bonetti
Correspondence

Breast cancer late recurrence is a topic poorly treated by the literature. In particular, the reported recurrence rate at ≥10 years for stage I–III primary breast cancer was 5.8 %, with overall 10-year cumulative disease-free survival (DFS) rate of 79.5 % [1]. To our knowledge, recurrence rate at ≥10 years for early breast cancer (pT1pN0) was not reported in literature. Actually, there is no clear definition of late recurrence regarding the number of years from the primary treatment. As other authors [1], we defined late recurrence as recurrence at ≥10 years.

Recently, Oven Ustaalioglu et al. [2] evaluated retrospectively 1980 breast cancer patients and they compared clinicopathological factors with respect to the time of recurrence between early (if it was occured first 5 years of follow-up) and late (if it was occured after 5 years). Recurrence was detected in 141 patient during follow-up. They found that tumors recurred after 5 years more likely to have lower stage (p = 0.05),...

Keywords

Early breast cancer Late recurrence Prognostic factors 

Notes

Compliance with ethical standards

Conflict of interest

None declared.

References

  1. 1.
    Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, et al. Evaluation of factors related to late recurrence later than 10 years after the initial treatment in primary breast cancer. Oncology. 2013;85:100–10.CrossRefPubMedGoogle Scholar
  2. 2.
    Oven Ustaalioglu BB, Balvan O, Bilici A, Develi A, Aliustaoglu M, Vardar FA, et al. The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival. Clin Transl Oncol. 2015. doi: 10.1007/s12094-015-1323-x.Google Scholar
  3. 3.
    Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from esca- lating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–83.CrossRefPubMedGoogle Scholar
  4. 4.
    Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res. 2014;20:1298–305.CrossRefPubMedGoogle Scholar
  5. 5.
    Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005;1:CD001768.PubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2015

Authors and Affiliations

  1. 1.Department of OncologyMater Salutis HospitalLegnagoItaly

Personalised recommendations